Insights from ELCC 2024
ELCC 2024 Insights: "Evaluating Safety & Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFRm NSCLC"
By
Insights from ELCC 2024
FEATURING
Xiuning Le
By
Insights from ELCC 2024
FEATURING
Xiuning Le
Comments 0
Login to view comments.
Click here to Login
